JP2022526890A5 - - Google Patents
Info
- Publication number
- JP2022526890A5 JP2022526890A5 JP2021556713A JP2021556713A JP2022526890A5 JP 2022526890 A5 JP2022526890 A5 JP 2022526890A5 JP 2021556713 A JP2021556713 A JP 2021556713A JP 2021556713 A JP2021556713 A JP 2021556713A JP 2022526890 A5 JP2022526890 A5 JP 2022526890A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- composition according
- cancer
- formula
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962822486P | 2019-03-22 | 2019-03-22 | |
| US62/822,486 | 2019-03-22 | ||
| US201962934930P | 2019-11-13 | 2019-11-13 | |
| US62/934,930 | 2019-11-13 | ||
| PCT/US2020/023913 WO2020198026A1 (en) | 2019-03-22 | 2020-03-20 | Compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526890A JP2022526890A (ja) | 2022-05-27 |
| JP2022526890A5 true JP2022526890A5 (enExample) | 2023-03-28 |
Family
ID=72611715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556713A Pending JP2022526890A (ja) | 2019-03-22 | 2020-03-20 | 化合物及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230078764A1 (enExample) |
| EP (1) | EP3941908A4 (enExample) |
| JP (1) | JP2022526890A (enExample) |
| KR (1) | KR20220003173A (enExample) |
| CN (1) | CN114174273A (enExample) |
| AU (1) | AU2020245349A1 (enExample) |
| BR (1) | BR112021018591A2 (enExample) |
| CA (1) | CA3134510A1 (enExample) |
| IL (1) | IL286497A (enExample) |
| MA (1) | MA55385A (enExample) |
| MX (1) | MX2021011488A (enExample) |
| SG (1) | SG11202110225SA (enExample) |
| WO (1) | WO2020198026A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| IL296790B1 (en) | 2020-03-30 | 2026-07-01 | Hutchmed Ltd | Amide compounds and their uses |
| WO2022104011A1 (en) * | 2020-11-12 | 2022-05-19 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| EP4253383A4 (en) * | 2020-12-31 | 2024-07-17 | Tsinghua University | PYRIDINE-2-AMINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE |
| MX2023014754A (es) | 2021-06-18 | 2024-02-12 | Aligos Therapeutics Inc | Métodos y composiciones dirigidos a pd-l1. |
| CN119212987A (zh) | 2021-12-16 | 2024-12-27 | 安力高医药股份有限公司 | 用于靶向pd-l1的方法和组合物 |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| WO2024112854A1 (en) | 2022-11-22 | 2024-05-30 | Odyssey Therapeutics, Inc. | Inhibitors of ripk2 and medical uses thereof |
| JP7894535B2 (ja) | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7271181B2 (en) * | 2001-05-11 | 2007-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| WO2006022442A1 (ja) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| EP2289510A1 (en) * | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| EP2027121A1 (en) * | 2006-05-22 | 2009-02-25 | Merck Frosst Canada Ltd. | Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US8080659B2 (en) * | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| WO2008008852A2 (en) * | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| NZ616097A (en) * | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| US20110183958A1 (en) * | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| MX342326B (es) * | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| WO2013070660A1 (en) * | 2011-11-07 | 2013-05-16 | Emory University | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| US8530461B2 (en) * | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| WO2015113920A1 (en) * | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
| WO2017112777A1 (en) * | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| EP3490561A4 (en) * | 2016-08-01 | 2020-04-08 | Ignyta, Inc. | COMBINATIONS FOR TREATING CANCER |
| MA47212A (fr) * | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| EP3381908A1 (en) * | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase |
| WO2018195450A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| ES3043183T3 (en) * | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
-
2020
- 2020-03-20 US US17/441,937 patent/US20230078764A1/en not_active Abandoned
- 2020-03-20 BR BR112021018591A patent/BR112021018591A2/pt not_active Application Discontinuation
- 2020-03-20 KR KR1020217034310A patent/KR20220003173A/ko not_active Ceased
- 2020-03-20 SG SG11202110225SA patent/SG11202110225SA/en unknown
- 2020-03-20 JP JP2021556713A patent/JP2022526890A/ja active Pending
- 2020-03-20 MA MA055385A patent/MA55385A/fr unknown
- 2020-03-20 EP EP20776951.4A patent/EP3941908A4/en not_active Withdrawn
- 2020-03-20 CA CA3134510A patent/CA3134510A1/en active Pending
- 2020-03-20 CN CN202080037767.5A patent/CN114174273A/zh active Pending
- 2020-03-20 AU AU2020245349A patent/AU2020245349A1/en not_active Abandoned
- 2020-03-20 WO PCT/US2020/023913 patent/WO2020198026A1/en not_active Ceased
- 2020-03-20 MX MX2021011488A patent/MX2021011488A/es unknown
-
2021
- 2021-09-19 IL IL286497A patent/IL286497A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015227454B2 (en) | Functionalised and substituted indoles as anti-cancer agents | |
| JP5808408B2 (ja) | フタラジノンケトン誘導体、その製造法および医薬用途 | |
| KR101586112B1 (ko) | 카바졸 화합물 및 이 화합물의 치료학적 용도 | |
| IL237831A (en) | Inhibitors of histone demethylases | |
| JP2008535903A5 (enExample) | ||
| IL261852A (en) | Substituted imidazole based compounds for treatment of cancer | |
| JP7319977B2 (ja) | チューブリン阻害剤 | |
| JP2007511504A5 (enExample) | ||
| BR112017003312B1 (pt) | Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
| JP2007523862A5 (enExample) | ||
| WO2009114994A1 (zh) | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 | |
| KR20210120070A (ko) | 면역조절제 | |
| RU2016147654A (ru) | Соединения для лечения рака | |
| AU2014273618A1 (en) | Imidazole diketone compound and use thereof | |
| CN104736155A (zh) | 双环化合物作为激酶的抑制剂 | |
| CN118119618A (zh) | 一种杂芳环类化合物及其应用 | |
| RU2003137007A (ru) | Новые пиридилцианогуанидиновые соединения | |
| KR102421137B1 (ko) | 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도 | |
| WO2021154668A1 (en) | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | |
| JP4707393B2 (ja) | 抗癌化合物 | |
| CN115210235A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 | |
| WO1999040093A2 (en) | Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents | |
| CN117343062A (zh) | 一种吡唑并嘧啶酮化合物、其制备方法和用途 | |
| WO2023020604A1 (zh) | 一种五元含氮杂环并杂芳基类衍生物及其用途 | |
| JP2025511112A (ja) | 芳香環化合物及びそれの使用 |